WallStSmart

Trio-Tech International (TRT)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 426% more annual revenue ($258.90M vs $49.22M). TRT leads profitability with a -0.2% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 38/100 (F).

TRT

Avoid

30

out of 100

Grade: F

Growth: 4.7Profit: 3.5Value: 5.3Quality: 5.0

ZEPP

Hold

38

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

TRTUndervalued (+5.0%)

Margin of Safety

+5.0%

Fair Value

$6.24

Current Price

$12.62

$6.38 discount

UndervaluedFair: $6.24Overvalued
ZEPPUndervalued (+48.9%)

Margin of Safety

+48.9%

Fair Value

$46.96

Current Price

$18.01

$28.95 discount

UndervaluedFair: $46.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TRT1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
81.6%10/10

Revenue surging 81.6% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

TRT4 concerns · Avg: 2.8/10
Market CapQuality
$134.71M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.3%3/10

ROE of 0.3% — below average capital efficiency

Operating MarginProfitability
0.6%3/10

Operating margin of 0.6%

EPS GrowthGrowth
-75.5%2/10

Earnings declined 75.5%

ZEPP4 concerns · Avg: 2.3/10
Market CapQuality
$270.28M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Free Cash FlowQuality
$-26.48M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : TRT

The strongest argument for TRT centers on Revenue Growth. Revenue growth of 81.6% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : TRT

The primary concerns for TRT are Market Cap, Return on Equity, Operating Margin.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

TRT carries more volatility with a beta of 1.99 — expect wider price swings.

TRT is growing revenue faster at 81.6% — sustainability is the question.

TRT generates stronger free cash flow (-152,000), providing more financial flexibility.

Monitor SEMICONDUCTOR EQUIPMENT & MATERIALS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (38/100 vs 30/100) and 43.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Trio-Tech International

TECHNOLOGY · SEMICONDUCTOR EQUIPMENT & MATERIALS · USA

Trio-Tech International provides manufacturing, testing and distribution services to the semiconductor industry. The company is headquartered in Van Nuys, California.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?